How ELISpot accelerates malaria vaccine development

Published: May 29, 2026

8 minute read

Malaria remains one of the world's most devastating infectious diseases. Despite decades of intervention efforts, Plasmodium falciparum malaria caused an estimated 249 million cases and 608,000 deaths in 2022, most of them in sub-Saharan Africa. While bed nets, rapid diagnostics, and antimalarial drugs have made significant progress, a highly effective vaccine has remained elusive – until recently.

The challenge is immunological: natural immunity to malaria develops slowly and incompletely, even after years of repeated exposure. Protective immunity requires both antibodies that neutralise parasites and cell-mediated responses that eliminate infected liver cells before parasites reach the blood. This is where ELISpot has become a critical tool.

ELISpot (enzyme-linked immunosorbent spot) assays measure antigen-specific T cell responses at single-cell resolution, making them ideal for tracking the cellular arm of vaccine-induced immunity. In malaria vaccine research, ELISpot has helped identify protective antigens, measure immune durability, and predict clinical efficacy – all essential steps toward developing a vaccine that works in the populations who need it most.

Malaria is spread by mosquitos

Why ELISpot for malaria research?

Malaria vaccine development faces unique challenges. The parasite has a complex life cycle with distinct antigenic stages, and protective immunity involves both humoral and cellular responses. Traditional antibody assays tell only part of the story – researchers also need to measure T cell responses that target infected hepatocytes during the pre-erythrocytic stage.

ELISpot offers several advantages in this context:

Sensitivity – ELISpot can detect rare antigen-specific T cells at frequencies as low as 1 in 100,000, essential when working with field samples from malaria-exposed populations where responses may be subtle.
Single-cell resolution – Unlike bulk assays, ELISpot quantifies the number of responding cells, providing insight into the magnitude of vaccine-induced responses.
Functional readout – By measuring IFN-γ secretion, researchers assess not just the presence of memory T cells but their ability to produce effector cytokines upon re-stimulation.
Field applicability – ELISpot protocols can be adapted for use in resource-limited settings, making it possible to conduct immunogenicity studies in malaria-endemic regions where genetic diversity and prior exposure patterns differ from controlled laboratory cohorts.

These features have made IFN-γ ELISpot a cornerstone assay in vaccine trials for P. falciparum, with many studies using it as a primary endpoint to assess vaccine immunogenicity.

Vaccine candidate screening

One of the earliest applications of ELISpot in malaria research is identifying which parasite antigens elicit protective T cell responses. Researchers use ELISpot to screen overlapping peptide pools spanning candidate antigens like circumsporozoite protein (CSP), apical membrane antigen 1 (AMA1), and thrombospondin-related adhesive protein (TRAP).

In a study of Ghanaian adults with natural malaria exposure, researchers used IFN-γ ELISpot to measure recall responses to AMA1 and CSP peptides. They identified immunodominant epitopes that triggered robust T cell responses in individuals who had developed partial immunity. These epitopes are now being incorporated into next-generation vaccine formulations designed to work across genetically diverse populations.

ELISpot also helps researchers understand why some antigens fail. Comparing responders and non-responders reveals whether lack of immunogenicity is due to poor antigen design, suboptimal adjuvants, or population-level differences in HLA alleles.

Measuring vaccine efficacy

Once a vaccine enters clinical trials, ELISpot becomes a key tool for tracking immunogenicity over time. Researchers measure IFN-γ-secreting T cells at baseline, post-vaccination, and during follow-up to assess the magnitude, kinetics, and durability of vaccine-induced responses.

In the landmark RTS,S/AS01 vaccine trials – the first malaria vaccine approved for use in children – ELISpot assays were used to measure CD4+ and CD8+ T cell responses to CSP. Early IFN-γ responses predicted later resting memory, and higher responders showed better protection against clinical malaria during the first year post-vaccination.

More recently, ELISpot has been used to evaluate next-generation vaccine platforms, including viral vectors, protein-in-adjuvant formulations, and mRNA vaccines. By comparing the magnitude and phenotype of T cell responses across platforms, researchers can optimize delivery strategies before moving to expensive phase III trials.

ELISpot also plays a role in correlates-of-protection analyses. By linking T cell readouts to clinical endpoints (time to infection, parasite density, disease severity), researchers identify immune thresholds associated with protective efficacy – guiding dose selection and booster schedules.

Real-world insights from the field

One of ELISpot's greatest strengths in malaria research is its adaptability to field settings. Unlike flow cytometry, which requires fresh samples and expensive equipment, ELISpot can be performed using cryopreserved peripheral blood mononuclear cells (PBMCs) and relatively simple plate readers – making it feasible to run large immunogenicity studies in sub-Saharan Africa, Southeast Asia, and other endemic regions.

In Kenya, researchers used a reversed B cell FluoroSpot assay to study malaria-specific memory B cells in children with natural exposure. The assay, run on the Mabtech IRIS reader, revealed that children who developed immunity had distinct patterns of antigen-specific B cell differentiation compared to those who remained susceptible. This work demonstrated that high-sensitivity immunoassays could be deployed in resource-limited settings when material is limited and analytical precision is essential.

In another study conducted in Ghana, ELISpot was used to measure ex vivo IFN-γ recall responses in adults exposed to P. falciparum. The researchers identified class I-restricted T cell epitopes that were consistently recognized across individuals, supporting the development of broadly protective vaccines. The study also highlighted the importance of testing vaccines in the populations where they will ultimately be used – immune responses in malaria-naïve volunteers often differ from those in semi-immune individuals living in endemic areas.

These real-world applications underscore a key advantage of ELISpot: it bridges the gap between controlled laboratory studies and the messy realities of field immunology, where prior exposure, co-infections, and genetic diversity all influence vaccine responses.

The path forward

Malaria vaccine development is entering a new era. The WHO recommendation of RTS,S/AS01 for widespread use in children marks a turning point, and next-generation candidates – including R21/Matrix-M, whole-sporozoite vaccines, and transmission-blocking vaccines – are advancing through trials. ELISpot will remain central to these efforts, helping researchers refine formulations, optimise prime-boost regimens, and identify immune signatures that predict long-term protection.

As vaccine platforms evolve, so too will the assays used to measure their success. Multiplexed FluoroSpot assays now allow simultaneous measurement of IFN-γ, IL-2, TNF-α, and other cytokines, revealing the quality and polyfunctionality of T cell responses. High-throughput automation is making it possible to screen hundreds of samples per week, accelerating the pace of discovery.

But the core principle remains the same: understanding immunity at the single-cell level. Whether screening new antigens, measuring vaccine responses in the field, or identifying correlates of protection, ELISpot provides the sensitivity, reproducibility, and functional insight needed to move malaria vaccines from the lab to the clinic – and ultimately, to the communities where they can save lives.

Ready to measure T cell responses in your malaria vaccine study?

Explore similar topics

Highlighted research ELISpot Human IFN-γ Infectious diseases Vaccines elispot vaccine infectious diseases